ClinicalTrials.gg
CompletedNCT03502434Updated Oct 1, 2026

A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers

A Phase 1 interventional study of SM04755 and Vehicle in Tendinopathy, sponsored by Biosplice Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Biosplice Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Nov 2017, 9 years ago, and no results have been posted to the registry.
  • Registered 6 months after the study started (first participant enrolled Sep 2017, registered Mar 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
223
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Tendinopathy with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Tendinopathy · United States.

Enrollment
6th of 89
223 · median 40
Started
2017
with 9 others
Phase 1
6 of 99
1 open now
Registered
52nd of 99
by date
Lead sponsor
2 of 99
Biosplice Therapeutics, Inc.

Among the 99 studies in Tendinopathy with a site in United States, this one is the 6th largest by enrollment of the 89 interventional ones that give a count, is one of 10 that started in 2017, is one of 6 in phase 1, and was the 52nd registered.

Tendinopathy

397 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.

Browse Tendinopathy studies →

Open to participants now

15 of the 99 studies in Tendinopathy with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Tendinopathy studies recruiting now, 17 (37%) set no upper age limit and 22 (48%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Tendinopathy with a site in United States, or all of them as a file.
02

Study summary

This is a single center, randomized, controlled, within subject comparison, single dose study to determine the sensitization potential of SM04755 solution on normal skin under semi-occlusive patch conditions.

Read the detailed description

This Phase 1, Repeat Insult Patch Test (RIPT) study is a single-center study of topical SM04755 solution repetitively applied to skin of healthy volunteers. This study will assess the potential of the Test Materials to induce contact sensitization as measured by treatment emergent adverse events (TEAEs), Reaction Grade and Investigator assessment of irritation and sensitization.

03

Conditions studied

  • Tendinopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males and females at least 18 years of age
  • Subjects of any Fitzpatrick skin type or race provided their degree of skin pigmentation does not, in the Investigator or designee's opinion, interfere with study assessments
  • Subject has no signs of irritation (i.e., a Reaction Grade of "0") at patch application sites on the back prior to the initial patch application on Day 1
  • Subject must have read, understood, and signed the form prior to any study-related procedure being performed
  • Subject is willing and able to comply with all scheduled study visits, urine pregnancy tests (if applicable), requirements (male and female), and other study requirements
  • Subject is willing to avoid extensive sun exposure, phototherapy, or use of a tanning salon for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Women of who are sexually active and are not willing to use a highly effective method of during the study period that includes double barrier, IUD, or hormonal contraceptive combined with single barrier, or abstinence
  • Women of childbearing potential who have had unprotected sexual intercourse within 30 days prior to Day 1
  • Males who are sexually active and not willing to use a condom, and have a partner who is capable of becoming pregnant, if neither has had surgery to become sterilized, and/or who are not willing to use double barrier or whose partner is not using a highly effective method of birth control (e.g., IUD, or hormonal contraception combined with single barrier)
  • Subject has any skin condition that, in the Investigator's opinion, could interfere with the study assessments or put the subject at undue risk by study participation
  • Subject has severe atopic dermatitis/eczema, psoriasis or chronic asthma
  • Subject has tattoos, excessive hair, moles, scarring, etc. which would interfere with patching
  • Subject has a history of sensitivity to any component of any of the Test Materials
  • Use of any of the following medications:
  • Systemic or topical within 4 weeks prior to Day 1
  • Systemic or topical analgesics (e.g., NSAIDs, high dose aspirin, etc.) within 1 week prior to Day 1. Note: Daily use of ≤325 mg of aspirin for cardiovascular disease or prophylaxis is allowed. Maximum daily use of Tylenol ≤3000 mg is allowed.
  • Antihistamines within 1 week prior to Day 1. Note: H2 blockers such as Pepcid, Zantac, and Tagamet are permitted.
  • Anti-inflammatories within 1 week prior to Day 1
  • medications (e.g., TNF-alpha inhibitors, topical tacrolimus, etc.) within 4 weeks prior to Day 1 (or within 6 half-lives prior to Day 1 for biologics)
  • Subject has had previous treatment with SM04755
  • Subject has an active infection of or C or (HIV) infection as determined by an interview
  • Participation in a clinical research trial that included the receipt of an product or any experimental therapeutic procedure within 8 weeks prior to Screening, or planned participation in any such trial; the last date of participation in the trial, not the last date of receipt of investigational product, must be at least 8 weeks prior to Screening
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    90 mg/mL SM04755 in water

    90 mg/mL SM04755 in water applied via patches

    Drug: SM04755

  • Experimental
    90 mg/mL SM04755 in aqueous Vehicle

    90 mg/mL SM04755 in aqueous Vehicle applied via patches

    Drug: SM04755

  • Experimental
    90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol)

    90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol) applied via patches

    Drug: SM04755

  • Other
    Vehicle

    Aqueous Vehicle applied via patches

    Other: Vehicle

  • Other
    White petrolatum

    White petrolatum (Negative control) applied via patches

    Other: White Petrolatum

  • Other
    Sodium lauryl sulfate

    Sodium lauryl sulfate (SLS 0.5%) (Positive control) applied via patches

    Other: Sodium lauryl sulfate

Interventions

  • DrugWnt Signaling Inhibitor SM04755Studies of Wnt Signaling Inhibitor SM04755Wnt Signaling Inhibitor SM04755 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.

  • OtherVehicle

    Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.

  • OtherWhite Petrolatum

    Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.

  • OtherSodium lauryl sulfate

    Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.

06

What researchers measure

Primary outcomes

  1. Contact sensitization potential of Test Material as measured by Treatment emergent

    Time frame: Baseline to Day 40 (or through the observation period for TEAEs)

  2. Contact sensitization potential of Test Material as measured by Reaction Grade

    Reaction Grade is measured on a 5-point scale from zero to four (zero = no sign of irritation and 4 = Erythema with edema and blistering)

    Time frame: Baseline to Day 38-40

  3. Contact sensitization potential of Test Material as measured by Investigator assessment of irritation and sensitization

    Time frame: Baseline to Day 40

07

Study locations

1 site
  • Research Site
    Lynchburg, Virginia 24503, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Nov 2017, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2018
First posted
Apr 18, 2018
StartActual
Sep 11, 2017
Primary completionActual
Nov 17, 2017
CompletionActual
Nov 17, 2017
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and index terms
1 update, last Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Minor edits only
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03502434
Responsible party
Sponsor
First posted
Apr 18, 2018
Start date
Sep 11, 2017
Primary completion
Nov 17, 2017
Completion
Nov 17, 2017
Last update
Oct 1, 2026

Study contacts

Yusuf Yazici, M.D.
study director · Biosplice Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Wnt Signaling Inhibitor SM04755

Start the discussion